These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 12445247)
21. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide. Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342 [TBL] [Abstract][Full Text] [Related]
22. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. Hainsworth JD; Burnett LS; Jones HW; Grosh WW; Johnson DH; Greco FA J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811 [TBL] [Abstract][Full Text] [Related]
23. Sequential combination of paclitaxel-carboplatin and paclitaxel-liposomal doxorubicin as a first-line treatment in patients with ovarian cancer. A multicenter phase II trial. Potamianou A; Androulakis N; Papakotoulas P; Toufexi H; Latoufis C; Kouroussis C; Christofilakis C; Xenidis N; Georgoulias V; Polyzos A Oncology; 2005; 69(4):348-53. PubMed ID: 16293974 [TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
27. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Kirmani S; Braly PS; McClay EF; Saltzstein SL; Plaxe SC; Kim S; Cates C; Howell SB Gynecol Oncol; 1994 Sep; 54(3):338-44. PubMed ID: 8088611 [TBL] [Abstract][Full Text] [Related]
28. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up. Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355 [TBL] [Abstract][Full Text] [Related]
29. A systematic overview of chemotherapy effects in ovarian cancer. Högberg T; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940 [TBL] [Abstract][Full Text] [Related]
30. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93). Schink JC; Weller E; Harris LS; Cella D; Gerstner J; Falkson C; Wadler S Cancer J; 2001; 7(2):155-64. PubMed ID: 11324769 [TBL] [Abstract][Full Text] [Related]
31. Chemotherapy of advanced ovarian cancer with 4'-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. Lévi F; Benavides M; Chevelle C; Le Saunier F; Bailleul F; Misset JL; Regensberg C; Vannetzel JM; Reinberg A; Mathé G J Clin Oncol; 1990 Apr; 8(4):705-14. PubMed ID: 2179481 [TBL] [Abstract][Full Text] [Related]
32. Phase I evaluation of thio-TEPA in combination with cisplatin for advanced gynecologic malignancies. Sandles LG; Freedman RS; Raber MN; Kavanagh J; Edwards CL; Scott WR; Wharton JT Gynecol Oncol; 1990 Nov; 39(2):139-45. PubMed ID: 2121628 [TBL] [Abstract][Full Text] [Related]
33. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168 [TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. Herben VM; Panday VR; Richel DJ; Schellens JH; van der Vange N; Rosing H; Beusenberg FD; Hearn S; Doyle E; Beijnen JH; ten Bokkel Huinink WW J Clin Oncol; 1999 Mar; 17(3):747-55. PubMed ID: 10071262 [TBL] [Abstract][Full Text] [Related]
36. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study. Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224 [TBL] [Abstract][Full Text] [Related]
37. Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting. Gordon AN; Stringer CA; Matthews CM; Willis DL; Nemunaitis J J Clin Oncol; 1997 May; 15(5):1965-73. PubMed ID: 9164208 [TBL] [Abstract][Full Text] [Related]
38. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer]. Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312 [TBL] [Abstract][Full Text] [Related]
39. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up. Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300 [TBL] [Abstract][Full Text] [Related]
40. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Armstrong DK; Bookman MA; McGuire W; Bristow RE; Schilder JM; Gynecol Oncol; 2007 Jun; 105(3):667-71. PubMed ID: 17368526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]